Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAN-90806 in Neovascular AMD
NCT02022540Phase 1Completed
- Sponsor
- PanOptica
- Start
- Feb 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PAN-90806 in neovascular age-related macular degeneration (NVAMD) (6 arms), sponsored by PanOptica. Primary endpoint: Safety and Tolerability at 3 months. Started Feb 2014; status: completed.
02
Drugs
PAN-90806
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02022540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022540.